GentiBio logo

GentiBio

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.

Visit Website

Founded

2020

Employees

Between 5 - 10 employees

Raised

$177,000,000

Headquarters Location

Seattle, WA

Public

FALSE

Acquired

FALSE

Founders

Andy Walker, Chandra Patel, Adel Nada

CEO

Adel Nada
To discover, search, filter and sort thousands of companies and job listings please sign in.
View all the data

Funding Rounds

$157,000,000

August 2021

$20,000,000

August 2020

You can find more tech companies and startups, with financial and hiring information by creating a free account.
Get Started